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Abstract — Aims: To investigate whether, in the treatment with chlordiazepoxide for outpatient alcohol withdrawal, there are advan-
tages of symptom-triggered self-medication over a fixed-schedule regimen. Methods: A randomized controlled trial in outpatient
clinics for people suffering from alcohol dependence (AD) and alcohol-related problems; 165 adult patients in an outpatient setting
in a specialized alcohol treatment unit were randomized 1:1 to either a symptom-triggered self-medication or tapered dose, using
chlordiazepoxide. Alcohol withdrawal symptoms, amount of medication, duration of symptoms, time to relapse and patient satisfac-
tion were measured. Patients assessed their symptoms using the Short Alcohol Withdrawal Scale (SAWS). Patient satisfaction was
monitored by the Diabetes Treatment Satisfaction Questionnaire. We used the Well-Being Index and the European addiction severity
index for the 1-year follow-up. Results: We found no differences in the quantity of medication consumed, time to relapse, well
being or treatment satisfaction. Conclusion: Symptom-triggered self-medication was as safe as fixed-schedule medication in treating
outpatients with AD and mild to moderate symptoms of AWS. The SAWS is a powerful monitoring tool, because it is brief and
permits the subject to log the withdrawal symptoms.
INTRODUCTION
Ninety-three percent of the Danish population above the age
of 15 consume alcohol on a regular basis and 860,000
Danish citizens have an alcohol intake exceeding the sensible
drinking limits set to 14 drinks per week for women and 21
drinks per week for men (one drink equals 12 g of pure
alcohol), according to the National Board of Health. A total
of 585,000 adults fulfil diagnostic criteria for hazardous
alcohol consumption and 140,000 adults for alcohol depen-
dence (AD), and these individuals are especially at risk of
developing the alcohol withdrawal syndrome (AWS).
There is general agreement that AWS is a condition that
occurs after shorter or longer periods of heavy alcohol intake
and is caused by neurophysiologic changes in the brain
(McKeon et al., 2008). The AWS consists of a cluster of
symptoms developing within 1–3 days after the last drink. In
the mild form of the syndrome tremor, hyperactivity, anxiety,
tachycardia, sweating and sleep disturbances are seen
(Table 1). Without treatment, patients may develop more
severe symptoms like hallucinations, seizures and delirium
tremens, which is a potentially lethal condition with a mor-
tality rate of 1–5% (Becker, 1998) even when treated.
Adequate treatment of AWS is important for the adherence of
patients with alcohol addictions to treatment as patients’ fear
of getting symptoms can be an obstacle to seeking alcohol
treatment (Becker, 1998; Gossop et al., 2002; Malcolm et al.,
2000). A sufficient treatment programme for detoxification
and withdrawal can reduce the severity of future attacks of
AWS (reduce kindling; Becker, 1998; Erwin et al., 1998) and
motivate the patients’ determination to move on to continuous
alcohol treatment and a period of abstinence.
Pharmacological treatment is important (Whitfield et al.,
1978) and benzodiazepines have been proved efficient in
treating AWS in several studies; benzodiazepines can prevent
seizures and delirium tremens (Holbrook et al., 1999; Ntais
et al., 2005). Furthermore, an antidote is available and has
made benzodiazepines the drugs of choice for treatment of
AWS (National Board of Health, 2006; National Board of
Health, 2006 2729 /id).
In Denmark, most patients with AWS are treated on an
outpatient basis either in alcohol treatment units or by their
general practitioner, while patients with more severe symp-
toms are treated as inpatients in medical or psychiatric hospi-
tal departments.
In the Alcohol Unit at Hvidovre Hospital, we used chlor-
diazepoxide according to a fixed-dosage schedule, tapering
the dose to zero over 8–10 days. No monitoring or systema-
tic documentation of symptoms was used unless the patient
complained of continuing clinical symptoms causing the
dose to be changed. A fixed-dosage scheme suffers from the
lack of individualized treatment, lack of monitoring and
documentation of symptoms, and a paternalistic view ham-
pering the patients’ motivation for continued adherence to
treatment. Studies from abroad (Jaeger et al., 2001) indicate
successful inpatient treatment of AWS using a symptom-
triggered schedule rather than a fixed-schedule medication.
Some studies suggest that even outpatients may profit from a
symptom-triggered medication therapy in terms of motivat-
ing patients for enrolment in alcohol treatment (Holbrook
et al., 1999; Ntais et al., 2005). Therefore, it is important to
implement a monitoring instrument in the treatment of AWS
in outpatient settings. A number of scales have been devel-
oped to monitor the AWS in inpatient settings but only the
Short Alcohol Withdrawal Scale (SAWS) developed by
Gossop et al.2002 has been used and validated in an outpati-
ent setting. No consensus exists regarding a standardized
monitoring of AWS (Saitz and O’Malley, 1997).
The aims of this study were to test the hypotheses that a
symptom-triggered self-medication and self-monitoring of
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AWS in outpatients would reduce the intake of medication
and the duration of symptoms, prevent relapse and increase
patient satisfaction compared with a fixed-schedule
medication.
METHODS
This study took place in public outpatient services in five
Copenhagen hospitals with affiliation to the medical and psy-
chiatric emergency rooms with10–15 patients admitted per
day with alcohol-related problems. The patient population
and design of the study have previously been described in
detail (Elholm et al., 2010).
In brief, consecutive outpatients aged 18 years or more
were consecutively assessed for inclusion. All patients fulfill-
ing ICD-10 diagnostic criteria for AD and the AWS were
evaluated by means of the European addiction severity index
(EuropASI). Patients were included if abstinence from
alcohol had lasted for <72 h prior to inclusion. Patients who
had been treated for AWS within the last week, with a
history of three or more attempts of outpatient detoxification
within the last month, allergy towards chlordiazepoxide or
using drugs with known interaction with chlordiazepoxide
were excluded. Furthermore, patients were excluded if they
had known severe psychiatric illness including the Wernicke/
Korsakoff Syndrome, suicidal behaviour, severe cardiac or
liver disease, type 1 diabetes, as well as pregnant or breast-
feeding women and fertile women without safe contracep-
tion. Finally, patients were excluded if the breath alcohol
concentration was >10 mg%.
After informed consent included, patients were random-
ized to fixed-schedule treatment or symptom-triggered treat-
ment with chlordiazepoxide. Randomization was performed
as block randomization, stratified according to the SAWS
score at the baseline (score < 12 or score > 12). Sealed envel-
opes were administered by a secretary instructed to hand out
the envelope with the lowest number from the block
indicated.
Fixed-schedule treatment
In the fixed-schedule group, 200 mg chlordiazepoxide was
prescribed as a starting dose with daily tapering of the dose
with 25 mg for patients with a SAWS score > 12 at the base-
line. For patients scoring SAWS <12 at the baseline, the
starting dose of chlordiazepoxide was 80 mg with daily
tapering of the dose with 10 mg. Patients were instructed to
take the medication in fixed daily doses as prescribed and
were offered an extra dose if necessary.
Symptom-triggered treatment
In the symptom-triggered group, patients scoring > 12 at the
baseline were prescribed a maximum daily dose of chlordia-
zepoxide of 300 mg for 10 days. For patients scoring SAWS
< 12, the maximum daily dose was 120 mg for 10 days.
These patients administered the medication according to their
symptoms with the possibility of taking extra doses if
necessary. All patients were instructed to bring back any
unused tablets.
Follow-up
Patients attended the outpatient clinic daily preferably for
10 days. To support abstinence, patients in both arms were
offered concurrent treatment with disulphiram and/or acam-
prosate, and monitored by breath alcohol levels. All patients
filled in the SAWS daily until they terminated treatment.
SAWS contains the 10 items shown in Table 1. Each
symptom was scored 0–3 points retrospectively for the last
24 h (0 = no symptoms, 3 = severe symptoms). Patients were
instructed to fill in the SAWS every day, preferably when
they woke up and to bring the SAWS to the outpatient
clinic. The points were transferred to their medical record.
Treatment was to be continued for at least 5 days and symp-
toms were monitored for 10 days.
The primary trial endpoints were time to SAWS score <12
and time to SAWS score <6.
Secondary endpoints were time to relapse, defined as time
to interview or questionnaire-monitored first drink.
Patients were followed for 1 year after randomization.
Patients self-monitored their experience with adverse reac-
tions from chlordiazepoxide on Day 10 on a 12 cm Visual
Analogue Scale; 12 cm, 0–4 cm indicated light discomfort,
4–8 cm some discomfort and 8–12 cm massive discomfort.
This scale was supplemented with the nurses’ clinical evalu-
ation on Day 10.
EuropASI was used to monitor the impact of alcohol on
daily life (baseline, 3, 6 and 12 months) (Scheurich et al.,
2000). We used the Well-Being Index (WHO-5) well-being
scale to monitor patients’ well-being during Days 1–14 and
every 3rd month until 1 year after randomization
(Bonsignore et al., 2001). The scale contains five questions
about patients’ well-being graduated from 0–5. The scores
were added and multiplied by 4. The scale ranges from a
minimum of 0 to a maximum of 100 with scores < 50 indi-
cating low well-being.
Patient satisfaction was assessed using the Diabetes
Treatment Satisfaction Questionnaire (DTSQ; Bech et al.,
2003). The scale contains six questions and each question
was scored from 0 to 6, where 0 indicates ‘very unsatisfied
with treatment’ and 6 indicates ‘very satisfied with
treatment’.
Table 1. The SAWS
Item None (0) Mild (1) Moderate (2) Severe (3)
Anxious
Feeling confused
Restless
Miserable
Problems with memory
Tremor (shakes)
Nausea
Heart pounding
Sleep disturbance
Sweating
The patients fill in the SAWS by ticking the appropriate box that best
describes each of the 10 symptoms in the previous 24 h. Each item is scored
on a four-point scale: 0 = no symptoms, 1 = mild symptoms, 2 = moderate
symptoms and 3 = severe symptoms. The scores are summed up to give a
total score.
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Ethical approval
All patients gave their informed consent to their partici-
pation, and the study was performed in accordance with The
Declaration of Helsinki. The project was approved by The
Danish National Committee on Biomedical Research Ethics,
(ref. no.01–063/03), The Danish Medicines Agency (ref. no.
2612–2264) and the Danish Data Protection Agency (ref. no.
2003–41–2937).
Statistical methods
Data were analysed according to the principles of intention
to treat. Non-parametric statistics were used in comparing
continuous data, and the χ2 test was used for bivariate stat-
istics. The level of significance was set to 0.05.
The primary endpoint was defined from the questionnaire
data as a time-to-event endpoint. An event time was defined
for the patient as the first day he or she had a SAWS of less
than or equal to a pre-specified cut-point. If the patient
experienced a SAWS score below the cut-points at one of
the days, the patient was registered as having had an event.
If not, the patient was censored, and the number of days the
patient had been in the trial was registered. Five variables
were subsequently used as covariates in a survival analysis,
and the log-rank test was used to evaluate the significance of
the effect of the covariates on the endpoint. Likelihood ratio
tests for different treatment effects in subgroups were also
carried out.
Mann–Whitney’s non-parametric test was used to compare
the accumulated use of tablets, side effects and quality of life
endpoints between the two treatment groups.
RESULTS
One hundred and fifty-three randomized patients completed
the study (Fig. 1). We excluded eight patients due to the use
of concurrent medication or illicit drugs. Two patients
wished to be anonymous. One patient had trouble under-
standing the SAWS and one had major depression.
Patient characteristics did not differ significantly across the
two treatment groups as seen from Table 2 although a
slightly more number of patients in the symptom-triggered
group lived alone (P < 0.05).
Time to SAWS score < 12 (P = 0.924) and 6 (P = 0.091),
respectively, did not differ between the two treatment groups
as displayed in Fig. 2. In men, the time to reach SAWS
score ≤ 12 was significantly longer than in women (P = 0.043;
data not shown), and in patients with an alcohol intake <20
drinks/day the time to SAWS ≤ 12 (P = 0.017) and ≤6
(P = 0.034) were significantly shorter compared with those
with an alcohol intake >20 drinks/day (Fig. 3).
The median cumulated dose of chlordiazepoxide was 725
mg in the symptom-triggered group and 875 mg in the
fixed-schedule group. This difference was minimal and not
statistically significant (Table 3). Likewise, median side-
effect scores did not differ significantly between the treat-
ment groups (Table 3).
According to the WHO-5 well-being scale, most individ-
uals scored <50 at inclusion, which is a well-known experi-
ence. At Day 14, most individuals scored >50, and the
median increase in the WHO-5 score was 32 and16 in the
symptom-triggered and fixed-schedule group, respectively,
and these differences were not significant (Table 3).
Furthermore, patient satisfaction (DTSQ score) did not
differ significantly between groups (Table 3). We tested for
different treatment effects in men and women (interaction)
and found a slightly better effect of symptom-triggered treat-
ment in women compared with men for time to SAWS
score < 12 (likelihood ratio test; P < 0.043) and time to
SAWS score < 6 (likelihood ratio test; P < 0.078), while there
was no significant interaction between treatment and age,
number of drinking days or amount of alcohol intake
(P > 0.05).
Forty six patients in the symptom-triggered group and 45
patients in the fixed-schedule group relapsed within the first
year. No difference in time to relapse was observed
(Table 3), and no statistical differences were observed
Fig. 1. Flow chart and randomization.
Table 2. Demographic and data on alcohol variables including ASI alcohol
score
Treatment group
Symptom-triggered
(n = 78)
Fixed-schedule
(n = 75)
Male (%) 87.2 80
Age, years median (range) 49 (20–68) 49 (20–68)
Civil status (%)*
Married/living together 51 70
Living alone 49 30
Job situation (%)
Job last 30 days 45 48
Other income 55 52
Mild AWS (SAWS < 12) (%) 24 27
Moderate AWS (SAWS > 12) (%) 76 73
Alcohol history
Units per day (%)
≤20 68.9 54.8
>20–≤30 20.3 23.3
>30 10.8 21.9
Alcohol intake continuously
(days) median (range)
30 (1–365) 25 (2–365)
Money used on alcohol last
30 days; DKK median (range)
2547 (0–10.000) 2948 (0–30.000)
ASI composite score alcohol
median (inter-quartile range)
0.65 (0.49–0.79) 0.68 (0.51–0.79)
Years of alcohol dependency,
median (range)
8 (1–34) 6 (1–37)
≤5 years of alcohol
dependency (%)
47.9 46.7
Only significant difference between groups was civil status (P < 0.05).
Otherwise none of the observed differences were significant (χ2 test or
Mann–Whitney test whenever applicable).
*P < 0.05.
DKK, Danish kroner.
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between groups when time to relapse was plotted in a
Kaplan–Meier plot (Fig. 4). One year after inclusion, 16 and
25%, respectively, of the symptom-triggered and fixed-dose
groups were still under disulphiram treatment and 26 and
19%, respectively, received selective serotonin reuptake
inhibitor (SSRI) treatment. None of the patients were still
under treatment with acamprosate or naltrexone.
DISCUSSION
We did not find any difference in time to relapse between
symptom-triggered and fixed-schedule treatment groups, and
patients were equally satisfied.
Patients with an alcohol consumption >20 units on a daily
basis were at a greater risk of having withdrawal symptoms
for a longer period than those with a lower consumption.
Males are at greater risk for experiencing AWS. The fact that
women constituted only 20 per cent of our study population
may partly explain this finding. A recent study has shown
that women more easily develop alcohol dependency with a
lower consumption of alcohol compared with men. Other
explanations could be that the duration of alcohol consump-
tion prior to inclusion was shorter in women.
Benzodiazepines are the drugs of choice for the treatment
of AWS as shown in numerous randomized controlled trials
(RCT), systematic reviews and meta-analyses (Holbrook
et al., 1999; Mayo-Smith et al., 2004; Ntais et al., 2005).
In inpatients, an RCT showed that symptom-triggered
administration of benzodiazepines was better than fixed-dose
administration with regard to the total administered dose as
well as the duration of treatment (Saitz et al., 1994). In
Fig. 2. Kaplan–Meier analysis of time to SAWS < 6 (left panel) and < 12 (right panel) for individuals assigned to symptom-triggered treatment schedule
(solid) and fixed-schedule treatment (dashed). Time to SAWS < 6; hazard ratio 1.38, P = 0.09 (log-rank test) and time to SAWS < 12; hazard ratio = 0.98,
P = 0.92.
Fig. 3. Kaplan–Meier analysis of time to SAWS ≤ 6 (left panel) and ≤ 12 (right panel) with alcohol intake <20 drinks/day (solid) and >20 drinks/day (dashed).
Time to SAWS < 6; hazard ratio 0.65, P = 0.034 (log-rank test) and time to SAWS < 12; hazard ratio = 0.66, P = 0.017.
Symptom-Triggered Withdrawal Treatment 321
by guest on January 16, 2017
D
ow
nloaded from
 
another RCT, Daeppen et al. 2002 showed that symptom-
triggered treatment resulted in a reduced total dose of oxaze-
pam compared with fixed-schedule treatment, and the
duration of treatment was shorter in the symptom-triggered
group. In a third non-randomized trial, the duration of treat-
ment was shorter in the symptom-triggered group, while
there was no difference in the total dose of chlordiazepoxide
between groups (Hardern and Page, 2005).
This generally positive result of symptom-triggered treat-
ment could not be confirmed in the present study, as we did
not observe any significant difference in the total consump-
tion of chlordiazepoxide between the two groups. One of
four patients had mild AWS, defined as a SAWS score <12
when they were included in the study. The severity of AWS
was equally distributed in the two treatment groups. Some
patients may have had treatment for alcohol withdrawal from
an outpatient clinic or from a hospital stay prior to inclusion
into the study. This may have influenced our results.
However, from an ethical point of view, we found it of
importance that patients be sober when receiving the infor-
mation about the study and the SAWS and giving their
informed consent.
The WHO-5 well-being scale was easy to administer for
the staff and patients. We used the DTSQ on Day 10 for the
measurement of patient satisfaction. A repetition of the DTSQ
after 4 weeks illustrating the development in patient satisfac-
tion would have strengthened our study. The DTSQ was
developed for patients with a chronic disease as type 1 dia-
betes. The results are used to calculate how well patients cope
with their disease. We chose DTSQ because it was easy and
quick to administer, and because diabetes and alcohol depen-
dency share the elements of chronic disease and issues of self-
control. There were no significant differences between the
two treatment groups in DTSQ scores The high scores may
indicate a ceiling effect as has been described in other studies
(Bradley et al., 2007). Therefore, we are sceptical as to the
future use of this questionnaire in patients with alcohol addic-
tion. DTSQ should be supplemented with other measures of
patient satisfaction with treatment, something we discovered
in the literature. On several meetings with the nurses in the
five alcohol units, we had reports that patients were satisfied
with the implication of their treatment. They also appreciated
the self-assessment of their symptoms using the SAWS , and
the nurses found that the SAWS was a valuable tool for edu-
cating the patients in taking care of their health and symptoms
during the treatment. These data were not picked up by the
formal DTSQ. Modern treatment of AD and its consequences
is a prolonged process, while treatment of AWS is short but
important because sufficient treatment in the acute phase will
motivate the patients’ decision to stay sober much easier as
well as a sufficient treatment of AWS may reduce future com-
plications. Many patients have experienced several episodes
of AWS, and the SAWS provides an easy and safe way of
self-monitoring and a good basis for administration of AWS
medication focusing on the individual. While the SAWS and
symptom-triggered treatment did not prove to have an advan-
tage, the use of SAWS helps in documenting AWS and its
treatment.
This is the first time that the SAWS has been tested in an
outpatient setting.
Outpatient medical detoxification is an effective, safe and
low-cost treatment for patients suffering from mild-to-
moderate AWS which can have a wide reach, although rating
procedures cannot replace medical staff evaluation.
CONCLUSION
This study showed high patient and staff satisfaction and
high compliance with self-monitoring of symptoms using the
Fig. 4. Kaplan–Meier analysis of time to relapse in the symptom-triggered
and fixed-treatment groups, P < 0.05.
Table 3. Use of medication, time to relapse, side effects, well-being and
patient satisfaction
Treatment group
Symptom-triggered
(n = 78)
Fixed-schedule
(n = 75)
Total dose of chlordiazepoxide mg;
median (range)
725 (50–2800) 875 (100–1900)
Side effects (median scores)
Dizziness 1.0 1.0
Fatigue 3.5 2.5
Poor concentration 6.0 2.0
Problems with memory 0.0 0.0
Feeling confused 1.5 0.0
WHO-5 day 1; score median (range) 24 (0–84) 36 (0–92)
WHO-5 change from Day 1–14
(median, range)
32 (−64–80) 16 (−60–80)
WHO-DTSQ score Day 10
(median, range)
36 (5–54) 35 (25–48)
Time to relapse, days
(median, range)
n = 39 n = 41
91 (14–355) 90 (10–365)
Relapses (n)
0–3 months 26 27
3–6 months 12 14
6–12 months 8 4
Differences between groups are not significant (Mann–Whitney test;
P > 0.05).
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SAWS. Symptom-triggered medication is as effective and
safe as the standard fixed-schedule treatment we use today.
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